



Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/800350
				Filing Date	March 12, 2004
				First Named Inventor	Valery Krasnoperov
				Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	VASG-P01-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US-2002/0146420-A1	10-10-2002	Brian Bennett	
	AB	US-5,624,899	04-29-1997	BRIAN D. BENNETT	
	AC	US-5,635,177	06-03-1997	BRIAN D. BENNETT	
	AD	US-5,864,020	01-26-1999	BRIAN D BENNETT	
	AE	US-6,303,769	10-16-2001	DOUGLAS P. CERRETTI	
	AF	US-6,413,730	07-02-2002	SACHA HOLLAND	
	AG	US-6,479,459	11-12-2002	DOUGLAS P. CERRETTI	
	AH	US-6,492,140-A1	07-26-2001	Douglas Cerretti	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>2</sup> -Number <sup>4</sup> -Kind Code <sup>3</sup> (if known)				
	BA	WO-00/24413	05-04-2000	The Walter and Eliza Hall Institute of Medical Research; The Council for the Queensland Institute of Medical Research; The University of Melbourne		
	BB	WO-00/30673	06-02-2000	Genentech, Inc.		
	BC	WO-02/058538	08-01-2002	Regeneron Pharmaceuticals, Inc.		
	BD	WO-02/061055	08-08-2002	Mount Sinai Hospital		
	BE	WO-02/079382	10-10-2002	The President and Fellows of Harvard College		
	BF	WO-02/102854	12-27-2002	Morphosys AG; Prochon Biotech Ltd.		
	BG	WO-02/102972	12-27-2002	Prochon Biotech Ltd.; Morphosys AG		
	BH	WO-02/102973	12-27-2002	Prochon Biotech Ltd.		
	BI	WO-02/11785	02-14-2002	University of Utah		
	BJ	WO-02/26827	04-04-2002	Novartis-Erfindungen Verwaltungsgesellschaft M.b.H.		
	BK	WO-03/004057	01-16-2003	The Hospital for Sick Children		
	BL	WO-93/15201	08-05-1993	New England Deaconess Hospital		
	BM	WO-95/27061	10-12-1995	Genentech, Inc.		
	BN	WO-96/01839	01-25-1996	Immunex Corporation		
	BO	WO-96/02645	02-01-1996	Genentech, Inc.		
	BP	WO-96/26958	09-06-1996	President and Fellows of Harvard College		
	BQ	WO-98/01548	01-15-1998	Mount Sinai Hospital Corporation		
	BR	WO-98/45708	10-15-1998	Sugen, Inc.		
	BS	WO-99/08696	02-25-1999	Vanderbilt University		

Examiner Signature		Date Considered	2-1-06
-----------------------	--	--------------------	--------

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/800350
				Filing Date	March 12, 2004
				First Named Inventor	Valery Krasnoperov
				Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	VASG-P01-002

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
[Signature]	CA	Adams, R.H., et al., "Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis," <i>Genes Dev.</i> , 13:295-306 (1999).		
	CB	Berclaz, G., et al., "Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma," <i>Ann Oncol.</i> , 14:220-226 (2003).		
	CC	Berclaz, G., et al., "Expression of the receptor protein tyrosine kinase myk-1/htk in normal and malignant mammary epithelium," <i>Biochem Biophys Res Commun.</i> , 24:226:869-875 (1996).		
	CD	Brambilla, R., et al., "Membrane-bound LERK2 ligand can signal through three different Eph-related receptor tyrosine kinases," <i>EMBO J.</i> , 14:3116-3126 (1995).		
	CE	Bruhl, T., et al., "Homeobox A9 Transcriptionally Regulates the EphB4 Receptor to Modulate Endothelial Cell Migration and Tube Formation," <i>Circ. Res.</i> , 743-751 (2004) [Epub ahead of print] DOI 10.1161/01res.0000120861.27064.09.		
	CF	Carbone, M., et al., "The pathogenesis of mesothelioma," <i>Semin. Oncol.</i> , 29(1):2-17 (2002).		
	CG	Cheng, N., et al., "The ephrins and Eph receptors in angiogenesis," <i>Cytokine &amp; Growth Factor Reviews</i> , 13:75-85 (2002).		
	CH	Cowan, C.A., et al., "Ephrins in reverse, park and drive," <i>Trends in Cell Biology</i> , 12(7):339-346 (2002).		
	CI	Davis, S., et al., "Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity," <i>Science</i> , 266(5186):816-819 (1994).		
	CJ	Fuller, T., et al., "Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cells," <i>J. Cell Sci.</i> , 116:2461-2470 (2003).		
	CK	Gerety, S.S., et al., "Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development," <i>Mol. Cell</i> , 4:403-414 (1999).		
	CL	Hamada, K., et al., "Distinct roles of ephrin-B2 forward and EphB4 reverse signaling in endothelial cells," <i>Arterioscler. Thromb. Vasc. Biol.</i> , 23:190-197 (2003).		
	CM	Himanen, J.P., et al., "Eph receptors and ephrins," <i>Intl. J. Biochem. &amp; Cell Bio.</i> , 35:130-134 (2003).		
	CN	Himanen, J.P., et al., "Eph signaling: a structural view," <i>Trends in Neurosciences</i> , 26(1):46-51 (2003).		
	CO	Hirai, H., "A novel putative tyrosine kinase receptor encoded by the eph gene," <i>Science</i> , 238:1717-1720 (1987).		
	CP	Kiyokawa, E., et al., "Overexpression of ERK, an EPH family receptor protein tyrosine kinase, in various human tumors," <i>Cancer Res.</i> , 54:3645-3650 (1994).		
CQ	Kullander, K., et al., "Mechanisms and functions of eph and ephrin signalling," <i>Nature Reviews, Molecular Cell Biology</i> , 3:475-486 (2002).			
CR	Mellitzer, G., et al., "Control of cell behavior by signalling through Eph receptors and ephrins," <i>Neurobiology</i> , 10:400-408 (2000).			
CS	Munarini, N., et al., "Altered mammary epithelial development, pattern formation and involution in transgenic mice expressing the EphB4 receptor tyrosine kinase," <i>J. Cell Sci.</i> , 115(Pt 1):25-37 (2002).			
Examiner Signature	[Signature]		Date Considered	2-1-06

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b>	
				Application Number	10/800350
				Filing Date	March 12, 2004
				First Named Inventor	Valery Krasnoperov
				Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	VASG-P01-002

<input checked="" type="checkbox"/>	CT	Nomura, A.M., et al., "Prostate cancer: a current perspective," Epidemiol Rev., 13:200-227 (1991).	
<input type="checkbox"/>	CU	Pasquale, E.B., "The Eph family of receptors," Curr. Opin. Cell Biol., 9:608-615 (1997).	
<input type="checkbox"/>	CV	Sakano, S., et al., "Characterization of a ligand for receptor protein-tyrosine kinase HTK expressed in immature hematopoietic cells," Oncogene., 13:813-822 (1996).	
<input type="checkbox"/>	CW	Schmucker, D., et al., "Signaling Downstream of Eph Receptors and Ephrin Ligands," Cell, 105:701-704 (2001).	
<input type="checkbox"/>	CX	Shin, D., et al., "Expression of ephrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of microvessels at sites of adult neovascularization," Dev. Biol. 230:139-150 (2001).	
<input type="checkbox"/>	CY	Sinha, U.K., et al., "Expression of EphB4 in head and neck squamous cell carcinoma," ENT J 82:721-723 (2003).	
<input type="checkbox"/>	CZ	Steinle, J.J., et al., "Eph B4 receptor signaling mediates endothelial cell migration and proliferation via the phosphatidylinositol 3-kinase pathway," J. Biol. Chem., 277(46):43830-5 (2002 Nov 15) (Epub 2002 Sep 13).	
<input type="checkbox"/>	CA1	Stephenson, S.A., et al., "Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer," BMC Mol. Biol., 2:15 (2001).	
<input type="checkbox"/>	CB1	Takai, N., et al., "Expression of receptor tyrosine kinase EphB4 and its ligand ephrin-B2 is associated with malignant potential in endometrial cancer," Oncol Rep., 8:567-573 (2001).	
<input type="checkbox"/>	CC1	Tang, X.X., et al., "Coexpression of transcripts encoding EphB receptor protein tyrosine kinases and their ephrin-B ligands in human small cell lung carcinoma," Clin. Cancer Res., 5:455-460 (1999).	
<input type="checkbox"/>	CD1	Wang, H.U., et al., "Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4," Cell 93:741-753 (1998).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	2-1-06
--------------------	---	-----------------	--------